Literature DB >> 8846652

Cyclosporine in rheumatoid arthritis: an overview.

O Førre1.   

Abstract

All the studies so far performed indicate that Cyclosporine (CyA) treatment i RA is effective and one study indicates that it can also slow down radiological progression. But it is also clear that CyA induced nephrotoxicity is so far the main problem. However, nephrotoxicity can be minimised by lowering the CyA dosage and by ensuring that RA patients subjected to CyA therapy have a normal kidney function and no history of hypertension. I believe that CyA alone or in combination with other drugs will find its place in the treatment of RA and other autoimmune diseases in the near future.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8846652     DOI: 10.1007/bf02215856

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  17 in total

1.  Longterm cyclosporine therapy in rheumatoid arthritis.

Authors:  A W van Rijthoven; B A Dijkmans; H S Goei Thè; M Boers; A Cats
Journal:  J Rheumatol       Date:  1991-01       Impact factor: 4.666

2.  Low-dose cyclosporin versus placebo in patients with rheumatoid arthritis.

Authors:  P Tugwell; C Bombardier; M Gent; K J Bennett; W G Bensen; S Carette; A Chalmers; J M Esdaile; A V Klinkhoff; G R Kraag
Journal:  Lancet       Date:  1990-05-05       Impact factor: 79.321

3.  Risk factors for cyclosporine-induced nephropathy in patients with autoimmune diseases. International Kidney Biopsy Registry of Cyclosporine in Autoimmune Diseases.

Authors:  G Feutren; M J Mihatsch
Journal:  N Engl J Med       Date:  1992-06-18       Impact factor: 91.245

4.  Renal side effects of high and low cyclosporin A doses in patients with rheumatoid arthritis.

Authors:  K J Berg; O Førre; O Djøseland; M Mikkelsen; J Narverud; H E Rugstad
Journal:  Clin Nephrol       Date:  1989-05       Impact factor: 0.975

5.  Side effects of cyclosporin A treatment in patients with rheumatoid arthritis.

Authors:  K J Berg; O Førre; F Bjerkhoel; E Amundsen; O Djøseland; H E Rugstad; B Westre
Journal:  Kidney Int       Date:  1986-06       Impact factor: 10.612

6.  Radiologic evidence of disease modification in rheumatoid arthritis patients treated with cyclosporine. Results of a 48-week multicenter study comparing low-dose cyclosporine with placebo. Norwegian Arthritis Study Group.

Authors:  O Førre
Journal:  Arthritis Rheum       Date:  1994-10

7.  Comparison of cyclosporine and D-penicillamine for rheumatoid arthritis: a randomized, double blind, multicenter study.

Authors:  A W van Rijthoven; B A Dijkmans; H S Thè; K A Meijers; Z L Montnor-Beckers; J D Moolenburgh; M Boers; A Cats
Journal:  J Rheumatol       Date:  1991-06       Impact factor: 4.666

8.  Evidence of an activated T-cell system with augmented turnover of interleukin 2 in rheumatoid arthritis. Stimulation of human T lymphocytes by dendritic cells as a model for rheumatoid T-cell activation.

Authors:  K Waalen; O Førre; M Linker-Israeli; J Thoen
Journal:  Scand J Immunol       Date:  1987-04       Impact factor: 3.487

9.  Regression of bone and cartilage loss in adjuvant arthritic rats after treatment with cyclosporin A.

Authors:  E del Pozo; M Graeber; P Elford; T Payne
Journal:  Arthritis Rheum       Date:  1990-02

10.  Morphological and functional renal effects of long-term low-dose cyclosporin A treatment in patients with rheumatoid arthritis.

Authors:  S Sund; O Førre; K J Berg; T K Kvien; T Hovig
Journal:  Clin Nephrol       Date:  1994-01       Impact factor: 0.975

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.